Author Archives:

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

Posted on by

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)




Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado.

The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection. Additionally, the ALG-097558 presentation showcases data from participants with hepatic and renal impairment. The ALG-097558 project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), under Contract No. 75N93023C00052.

“We are pleased to continue showcasing the best/first-in-class pevifoscorvir sodium data from the Phase 1 study in participants with chronic HBV infection,” said Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics. “Additionally, we continue to move our COVID program forward with grants from government agencies and are pleased to show some of this important clinical work at CROI this year.”

Details of the presentations are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection 

Poster #: 588
Title: High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy
Presenter: Stanley Wang, MD
Date/Time: February 23, 2026, 2:30pm – 4:00pm MST
Session: Beyond the C: Hepatitis D, B, and E

ALG-097558: Potential best-in-class ritonavir-free small molecule pan-coronavirus protease inhibitor

Poster #: 737
Title: Pharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor, in Renal and Hepatic Impairment
Presenter: Megan Fitzgerald, PhD
Date/Time: February 25, 2026, 2:30pm – 4:00pm MST
Session: SARS-CoV-2 Therapy, Consequences, and Outcomes

The presentations can be found on the Posters & Presentations section of the Aligos website (www.aligos.com) after the live event.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com

Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology

Posted on by
  • Biosimilar Ranluspec approved by European Commission for treatment of neovascular (wet) age-related macular degeneration (nAMD) and other retinal vascular disorders
  • Around four million people across key global markets live with nAMD; between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy
  • Launch expected second half of 2026; potential to expand access to life-changing treatment option for European patients
     

Basel, February 23, 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today confirmed that the European Commission has granted marketing authorization for Ranluspec1. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package.

Ranluspec is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis®*2.

Around four million people are estimated to have neovascular age-related macular degeneration in France, Germany, Italy, Spain, the UK, the US and Japan3, and between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy4. The approval paves the way for an expected launch of Ranluspec in the second half of 2026.

Claire D’Abreu-Hayling, Chief Scientific Officer, Sandoz, said: “Retinal diseases, including nAMD, place a significant burden on millions of patients, families and caregivers in Europe. The approval of Ranluspec reinforces our commitment to expanding the availability of high‑quality biosimilars and transforming healthcare by ensuring that patients can access these life‑changing treatments.”

Today’s announcement builds on the continuing leadership and pioneering legacy Sandoz has established in biosimilars, which began with the introduction of the first biosimilar, Omnitrope® (somatropin), in 2006. It strengthens the company’s position in ophthalmology, following the launch of Afqlir® (aflibercept) in Europe in 2025 and also represents another step towards the overall Sandoz strategic objective of capitalizing on a projected ~USD 320 billion biosimilar-market opportunity over the next 10 years5.

Sandoz and Lupin announced a commercial partnership in August 2025 for the development and commercialization of a ranibizumab biosimilar. Under the terms of the agreement, Sandoz holds exclusive commercialization rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France. Sandoz is commercializing Epruvy® (ranibizumab) in Germany under a separate agreement.

* Lucentis® is a registered trademark of Genentech Inc.

DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

REFERENCES
1 European Medicines Agency (EMA). Ranluspec® (ranibizumab): Product Details. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ranluspec [Last accessed: February 2026]
2 European Medicines Agency (EMA). Lucentis® (ranibizumab): Prescribing Information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis [Last accessed: February 2026]
3 DRG Clarivate Landscape and Forecast. Dry and Wet Age-Related Macular Degeneration. Report December 2024
4 Eye disease (2024) IDF Europe Site. Available at: https://idf.org/europe/life-with-diabetes/diabetes-related-complications/eye-disease/ [Last accessed: February 2026]
5 Covers US and EU markets (2026–2035). Originator sales and LoE based on internal analysis of data from multiple subscription databases. Biosimilar data accessed in September 2025

ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951 and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.

CONTACTS

Global Media Relations contacts

Investor Relations contacts

Global.MediaRelations@sandoz.com

Investor.Relations@sandoz.com

Alexis Kalomparis
+41 792 790285

Craig Marks

+44 7818 942 383

Chris Lewis

+49 174 244 9501

Tamara Hackl

+41 79 790 5217

Gregor Rodehueser

+49 170 574 3200

Silvia Siegfried

+41 79 795 9061

AOP Health on Rare Diseases: Information. Collaboration. Innovation.

Posted on by

AOP Health on Rare Diseases: Information. Collaboration. Innovation.




AOP Health on Rare Diseases: Information. Collaboration. Innovation.

Why closing knowledge gaps matters for patients, healthcare and innovation.




VIENNA–(BUSINESS WIRE)–#AOPHealth—Between 27 and 36 million1 people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment2. Progress in diagnosis and treatment is often slowed by knowledge gaps, including the lack of clear, reliable, and patient-friendly information needed to support informed decision-making. Drawing on 30 years of experience in researching and developing therapies for rare diseases, AOP Health underscores the importance of collaboration across the healthcare community. On Rare Disease Day 2026, the company joins healthcare professionals, researchers and patient representatives in highlighting the need for closer cooperation to generate, share and better use scarce data to improve care for people living with rare diseases.

“Working in rare diseases since 1996 has shown us that innovation is never a solo effort,” emphasized Melissa Fellner, Vice President Global Therapeutic Areas at AOP Health. “It requires continuous investment in data, open collaboration and information that reaches patients in a form they can use.”

Consistent with this approach, AOP Health is conducting five clinical studies in the field of rare diseases. The company collaborates with researchers at numerous renowned international universities, as well as 58 patient organizations, most of which focus on rare diseases. These partnerships aim to leverage synergies and to strengthen the evidence base.

Collaboration is key

Prof. Dr. med. Haifa Kathrin Al-Ali, a professor of internal medicine at Halle (Saale) University Hospital and Director of the Krukenberg Cancer Center Halle, shares AOP Health’s perspectives. ” Without informed patients, it is difficult to generate evidence that truly represents daily clinical reality,” she said. “Close collaboration and an exchange on equal footing are therefore essential, especially in rare diseases.”

Thus, cooperation between physicians, patients and the pharmaceutical industry plays a crucial role in advancing research.

New EU regulations require informed patients

Furthermore, patient involvement is becoming increasingly central to European evaluation and decision-making processes. New frameworks, such as joint clinical assessments (JCAs), and structured evaluation approaches, such as PICO (which defines populations, comparators, and patient-relevant outcomes), explicitly rely on evidence that reflects real-world needs and experiences. Therefore, robust, patient-relevant data and informed patient perspectives are becoming increasingly critical.

However, meaningful patient participation in these processes requires access to appropriate knowledge and competencies. Eva Otter, Vice President of PHA Europe, a patient advocacy group representing people living with pulmonary hypertension globally emphasizes, “To meet European requirements and participate effectively in evaluation processes, we need access to reliable, evidence-based information presented in a language we can understand. Patient-friendly expert information is therefore not an add-on, but a prerequisite for informed participation and credible assessments.”

Rare Disease Day 2026: Extending access to patient-centred information

To coincide with Rare Disease Day 2026, AOP Health is releasing a new episode of its German-language patient podcast to support patients in processing their diagnosis. This episode focuses on health literacy and addresses a central question: How can patients become well-informed and actively engaged in their care?

Links

Take a look at aop-health.com from 26.2.-2.3.2026 for a Rare Disease Day special and listen to the podcast „Ab jetzt ist alles anders? Leben nach und mit einer schwerwiegenden Diagnose“. (“Everything’s Different Now? Life After and With a Serious Diagnosis”) here.

About AOP Health

AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim “Needs. Science. Trust.” the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company’s actions. (aop-health.com)

1 https://health.ec.europa.eu/european-reference-networks/rare-diseases_en
2 https://www.eurordis.org/rare-disease-policy/european-policy/

Contacts

Further inquiry
DI Isolde Fally

Isolde.Fally@aop-health.com
https://www.aop-health.com

RE+Vitalize Health and Nutrition Announces Initiative to Advance Clean and Transparent Supplement Standards

Posted on by

RE+Vitalize Health and Nutrition Announces Initiative to Advance Clean and Transparent Supplement Standards




RE+Vitalize Health and Nutrition Announces Initiative to Advance Clean and Transparent Supplement Standards

Elizabeth City, NC, Feb. 23, 2026 (GLOBE NEWSWIRE) — RE+Vitalize Health and Nutrition, a retail health and nutrition brand based in Elizabeth City, announced an initiative focused on advancing clean and transparent supplement standards for consumers seeking straightforward wellness products. The initiative centers on ingredient transparency, product clarity, and educational resources intended to help individuals better understand nutrition labeling and supplement selection.

REVITALIZE Health and Nutrition 100% Isolate Whey Protein

The company stated that the initiative reflects a broader industry shift toward greater disclosure and accountability in dietary supplements, as consumers increasingly seek products with clearly identified ingredients and simplified formulations. RE+Vitalize Health and Nutrition is aligning its product development and retail practices with these expectations by emphasizing transparent labeling and accessible product information.

While the company’s 100% Isolate Whey Protein serves as a flagship example of its clean formulation standards, RE+Vitalize Health and Nutrition offers a broad portfolio of supplements designed to support overall wellness. The product line includes multivitamins, omega-3 fish oil, sleep aids, creatine, pre-workout formulas, probiotics, BCAAs, glutamine, and additional targeted nutritional supplements. This comprehensive range reflects the company’s commitment to supporting customers at every stage of their health journey, from foundational daily nutrition to performance-focused supplementation.

“Consumers are paying closer attention to what is in their supplements and how those products are formulated,” said owners Rick Anderson and Calvin Bright III. “This initiative is intended to provide clear information and straightforward options for people who want to make informed decisions about nutrition.”

Industry Context and Consumer Trends

Consumer interest in clean supplements and transparent nutrition has increased as more individuals prioritize ingredient quality and brand credibility. Industry research and market trends indicate that many adults prefer products with fewer additives, clear labeling, and accessible educational content. This shift has influenced product development across the wellness sector and prompted brands to adopt clearer disclosure practices.

RE+Vitalize Health and Nutrition stated that its initiative is designed to address these trends by reinforcing its commitment to ingredient transparency and simplified product information. The company is also expanding educational materials to support consumer understanding of supplement labels and general nutrition concepts.

Focus on Ingredient Transparency

As part of the initiative, RE+Vitalize Health and Nutrition is continuing to provide detailed ingredient disclosures and product information across its supplement offerings. The company indicated that product labels and online descriptions are structured to help consumers identify ingredient composition and intended use without technical complexity.

“Our goal is to remove unnecessary ambiguity from supplement labels,” the owners said. “Clear disclosure supports informed purchasing decisions and aligns with growing expectations for transparency in this category.”

The company emphasized that the initiative does not introduce new product claims but instead focuses on disclosure practices and educational outreach. RE+Vitalize Health and Nutrition’s approach is intended to reflect evolving regulatory and consumer expectations for clarity in dietary supplement labeling.

Educational Resources and Consumer Awareness

In addition to labeling practices, the initiative includes an expansion of educational content available through the company’s website and social media platforms. These materials are designed to explain common supplement ingredients, labeling terminology, and general nutrition concepts.

RE+Vitalize Health and Nutrition stated that education is a core component of its strategy to support consumer understanding and foster long-term trust. The company plans to continue developing informational resources that address common questions related to supplements and wellness.

“Education is a critical part of transparency,” according to them. “Providing accessible information can help consumers better understand product labels and the role of supplements in daily routines.”

Community Engagement in Elizabeth City

RE+Vitalize Health and Nutrition operates its retail location in Elizabeth City and is expanding its engagement with the local community as part of the initiative. The company indicated that it plans to participate in local outreach efforts and maintain open communication with customers seeking information about nutrition and supplements.

REVITALIZE Health & Nutrition works in partnership with REVITALIZE Fitness, the company’s training facility in Elizabeth City. Together, the two brands support a shared mission: to raise the standard for everyday wellness through clean, transparent supplements and accessible fitness guidance. This combined approach reflects the company’s commitment to helping individuals make informed, confident decisions about their health, both in the gym and in their daily routines. By integrating supplementation with hands-on fitness coaching, the REVITALIZE ecosystem provides a comprehensive wellness experience rooted in accountability, education, and community support.

The initiative is intended to strengthen the company’s presence in the region and support community members seeking straightforward wellness information. RE+Vitalize Health and Nutrition noted that its retail operations and digital platforms serve as complementary channels for product information and educational content.

Positioning Within the Wellness Market

The initiative positions RE+Vitalize Health and Nutrition within a segment of the wellness market focused on transparency and simplified product communication. The company stated that its strategy aligns with broader market trends favoring accountability, ingredient disclosure, and consumer education.

RE+Vitalize Health and Nutrition’s products are designed for adults seeking straightforward nutrition options that fit into daily routines. The company indicated that its approach prioritizes clarity and disclosure rather than marketing-driven claims.

“Transparency and clarity are becoming baseline expectations in this industry.” “This initiative is intended to align our practices with those expectations and contribute to ongoing discussions around supplement standards.”

Digital and Retail Presence

RE+Vitalize Health and Nutrition’s initiative includes updates to its digital content and in-store information resources. The company’s website provides product details and educational materials, while social media channels are used to share informational content related to nutrition and supplements.

Consumers can follow RE+Vitalize Health and Nutrition on Facebook and on Instagram for updates, educational content, and community engagement initiatives.

The company stated that digital platforms will continue to be used to distribute educational resources and provide access to product information. Retail operations will also include printed materials to support customer understanding of supplement labeling and ingredient disclosure.

Announcement Purpose

RE+Vitalize Health and Nutrition stated that the purpose of the initiative is to formalize and communicate its approach to ingredient transparency and consumer education. The company emphasized that the announcement is intended to inform stakeholders, customers, and the broader wellness community about its standards and practices.

The initiative reflects the company’s stated mission to raise standards in the supplement industry through transparency, education, and community-driven values. RE+Vitalize Health and Nutrition indicated that it will continue to evaluate and update its practices in response to evolving consumer expectations and regulatory guidance.

Consumers interested in learning more about RE+Vitalize Health and Nutrition and its approach to transparent supplement standards can visit the company’s website for product information and educational materials.

Founder Vision and Leadership

RE+Vitalize Health and Nutrition was founded by Rick Anderson, whose vision was to create a supplement brand built on transparency, clean ingredients, and straightforward education. Anderson later brought in Calvin Bright III as a partner to help expand the company’s mission and deepen its impact within the community. Together, they combine experience in fitness, nutrition, and consumer education to guide the brand’s commitment to honest labeling, simplified formulations, and accessible wellness resources. Their leadership continues to shape the company’s dual focus on product integrity and community empowerment.

About RE+Vitalize Health and Nutrition

RE+Vitalize Health and Nutrition is a health and nutrition retail brand based in Elizabeth City, North Carolina. The company focuses on clean ingredients, transparent supplement formulas, and accessible educational resources for consumers. Its products are designed for adults seeking straightforward nutrition options supported by clear labeling and ingredient disclosure. RE+Vitalize Health and Nutrition is committed to transparency, education, and community engagement within the wellness industry.

REVITALIZE Health & Nutrition


Media Contact
Company Name: RE+Vitalize Health and Nutrition
Contact Person: Rick Anderson
Email: revitalizehealthandnutrition@gmail.com
Phone: 252-621-1151
Country: United States
Website: https://www.revitalizehealthandnutrition.com/

CONTACT: Media Contact
Company Name: RE+Vitalize Health and Nutrition
Contact Person: Rick Anderson
Email: revitalizehealthandnutrition@gmail.com
Phone: 252-621-1151
Country: United States
Website: https://www.revitalizehealthandnutrition.com/

Pulselight platform now available to NHS via £10bn Fortrus Framework

Posted on by

Pulselight platform now available to NHS via £10bn Fortrus Framework




Pulselight platform now available to NHS via £10bn Fortrus Framework

Pulselight’s platform can now be procured for NHS organisations via this pre-approved route to market

LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) — Pulselight, a leading healthcare data analytics provider, is now an authorised partner on the £10bn capacity Fortrus Digital Enablement Framework (“the framework”), giving NHS organisations a fast, compliant route to procure advanced data analytics without lengthy tender processes.

With NHS trusts facing a projected deficit of £2.2 billion in 2025/26, and productivity improvement targets of 4 per cent, more than four times the NHS’s historical rate, the pressure to identify and recover lost value across the system has never been greater. The framework, established by the Countess of Chester Hospital NHS Foundation Trust and compliant with OJEU and Public Contracts Regulations 2015, enables faster implementation against targeted outcomes with significantly reduced procurement timelines and costs.

Pulselight’s platform is compatible with existing NHS data systems and can integrate and analyze data using advanced analytics to detect payment inaccuracies, duplicate assessments, and misallocated resources. Pulselight surfaces real time findings that would take manual reviews weeks to uncover, or insights that may be impossible to detect given data and system complexities.

Irene Manautou, Founder and CEO at Pulselight, said: “The Fortrus Framework provides NHS organisations with a clear and compliant route to adopt advanced analytics at a time when reducing waste, managing waiting lists, improving efficiency and reducing duplication are critical to long-term sustainability. Pulselight’s platform can help NHS teams identify inefficiencies earlier, invest in prevention, and support community-based care. Every pound should deliver maximum impact for patients”.

NHS organisations interested in accessing Pulselight’s platform through the framework can find further information at website.

For further information, please contact:
Pulselight (Team@Pulselight.com)
Irene Manautou

For Media Enquiries:
5654 & Company (Pulselight@5654.co.uk)
Matthew Neal, Partner (07917 800 011)
Charlotte Dawson, Associate Director (07810 406 284)

Notes to editors

About Pulselight

Pulselight a data and analytics company – has developed analytical products capable of transforming the health system.

Already delivering results in the US, Pulselight’s technologies maximise resources, deliver preventive health care, tackle health inequalities, and empower community health workers.

For more information, please visit: https://www.pulselight.com/

Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial Following CTA Approval for OPT101

Posted on by

Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial Following CTA Approval for OPT101




Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial Following CTA Approval for OPT101

MUTTENZ, Switzerland, Feb. 23, 2026 (GLOBE NEWSWIRE) — Opterion Health AG today announced that the first patient has been successfully enrolled in its Phase 1 SPARC trial. This marks the official start of the company’s first-in-human clinical development program for OPT101, its non-glucose-based osmotic agent designed to transform peritoneal dialysis (PD). This milestone follows the Clinical Trial Application (CTA) approval recently granted by the European health authorities, clearing the way for study initiation. 

The Phase 1 SPARC trial evaluates safety, tolerability, and pharmacokinetics across multiple OPT101 concentrations during controlled day and night dwell cycles, alongside patient-reported outcomes. The data will guide the next stages of development aimed at replacing today’s glucose-based solutions.

“First patient enrolled is a powerful and motivating moment for the entire organization,” said Peter Reinemer, Chief Executive Officer of Opterion Health AG. “For more than three decades, patients on peritoneal dialysis have had to rely on glucose-based solutions that come with significant compromises. With OPT101, we are determined to give patients with chronic kidney disease (CKD) better options. Today’s milestone proves we are well on our way.” 

Maxim Voropaiev, Chief Medical Officer, added: “First patient in gives us the clinical starting point we need. SPARC will tell us how OPT101 behaves, how patients experience it, and how we should shape future phases. Everything we learn from this study moves us closer to offering a therapy that reduces metabolic burden and supports longer-lasting, more patient-friendly PD care.” 

For more than 30 years, PD patients have relied on glucose-based solutions that drive metabolic distress, insulin spikes, weight gain, and which lead to glucose toxicity — a key driver of progressive peritoneal membrane deterioration. OPT101 is designed to change this dynamic, addressing long-standing unmet needs in a fast-growing global CKD population.

About Opterion Health AG
Opterion Health AG is a Swiss-based biopharmaceutical company focused on transforming renal care through the development of novel therapies for peritoneal dialysis patients. Its lead candidate, OPT101, is designed to improve the quality of life of patients undergoing peritoneal dialysis and changing the odds of PD outcomes for those who rely on life-saving treatments.

For further information, please contact:
info@opterion.com
www.opterion.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/09d91a22-d45f-4dd9-855b-2793e8b243d2

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Posted on by

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)




Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

  • Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
  • Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
  • Phase III program in food allergy (FA) planned for H2 2026

Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton’s tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontaneous urticaria (CSU) and as an investigational therapy for peanut allergy at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, from February 27 to March 2, 2026. These presentations provide more evidence on the use of Rhapsido in CSU, as well as its potential in other indications and highlight Novartis commitment to addressing unmet needs in patients with immune-mediated diseases.

New analyses on the impact of Rhapsido on disease control and early symptom relief from the Phase III REMIX-1 and REMIX-2 trials in CSU will be presented. Additionally, the first presentation of Phase II FA data for remibrutinib, focusing on IgE‑mediated peanut allergy, will be featured in an oral session. Plans are in progress to begin the Phase III program in FA in 2026.

“These food allergy (FA) data further strengthen the evidence supporting remibrutinib as a novel, well-tolerated, oral option for patients with allergic and immune-mediated diseases, complementing the recent FDA approval in chronic spontaneous urticaria (CSU) and underscoring its broader therapeutic potential,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Our priority is advancing therapies for patients who have few alternatives and expanding the reach of innovative medicines to transform care across multiple, high-need disease areas.” 

Regulatory reviews for remibrutinib for the treatment of CSU are underway in several regions, including the European Union and Japan.

In addition to FA, remibrutinib is in clinical development for chronic inducible urticaria (CIndU) and hidradenitis suppurativa (HS). FDA submission for remibrutinib in symptomatic dermographism, the most prevalent type of CIndU, was completed in Q4 2025. Additionally, positive topline results were announced for the remaining two arms of the CIndU Phase III RemIND trial. In the coming months, the full data set will be submitted to health authorities globally, and the RemIND trial findings will be presented at upcoming medical congresses.

Abstracts accepted by AAAAI include:

Abstract Title Abstract Number/Presentation Details
Efficacy and safety of remibrutinib, a Bruton’s tyrosine kinase inhibitor, for individuals with IgE-mediated peanut allergy Abstract #563
Oral Presentation
Saturday, February 28
2:45-2:55 PM EST
Remibrutinib Decreases Urticaria Disease Activity Leading To Improved Disease Control: An Analysis From The REMIX-1/-2 studies Abstract #822
Poster
Sunday, March 1
3:30-5:00 PM EST
Remibrutinib Provides Fast Symptom Relief Within the First Week of Treatment in Chronic Spontaneous Urticaria, as Measured by Daily Urticaria Activity Score: Pooled REMIX-1/-2 Studies Abstract #039
Poster
Friday, February 27
2:45-3:45 PM EST
Patients with Chronic Spontaneous Urticaria (CSU) in the US (United States): Health Care Resource Utilization (HCRU) by Level of Disease Control Abstract #021
Poster
Friday, February 27
2:45-3:45 PM EST

 
A Novel Panel of Autoantibodies May Assist In The Molecular Diagnosis of CSU Abstract #022
Poster
Friday, February 27
2:45-3:45 PM EST
   

About Novartis Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #
  

Novartis Media Relations
E-mail: media.relations@novartis.com

    
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com		  

argenx to Present at TD Cowen 46th Annual Healthcare Conference

Posted on by

argenx to Present at TD Cowen 46th Annual Healthcare Conference




argenx to Present at TD Cowen 46th Annual Healthcare Conference

February 23, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Operating Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2 at 11:50 a.m. ET.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

Almirall’s 2025 Results

Posted on by

Almirall’s 2025 Results




Almirall’s 2025 Results

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe


  • Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.
  • This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).
  • The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch.
  • Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists.
  • Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China.
  • Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.

BARCELONA, Spain–(BUSINESS WIRE)–Almirall, S.A. (ALM):

2025

2024

Variation

Total Revenue

1,114.5

990.6

12.5 %

Net Sales

1,108.1

985.7

12.4 %

Other Income

6.4

4.9

30.6 %

Gross Profit

713.3

637.4

11.9 %

% of sales

64.4%

64.7%

 

Total EBITDA

232.9

192.6

21.0 %

Normalised Net Income

52.6

25.6

105.5 %

Net Income

46.2

10.1

n.m.

“2025 was another important year for Almirall as we continue to deliver against our sustained growth trajectory and further expand our leadership in medical dermatology. Another year of double-digit growth of both net sales at 12.4% and EBITDA at 21.0%, demonstrates Almirall’s strong business performance and focus on executional excellence. Our broad portfolio of dermatology products is the driver of Almirall’s increasing relevance to patients and the medical community with our advanced biologics Ilumetri® and Ebglyss® leading our overall growth.

We are very pleased that our solid business performance enables us to continue to invest around 12.5% of our sales in advancing our exciting R&D pipeline that offers future opportunities to patients, the medical community, and for the long-term growth of Almirall. We are very confident in our strategy, commercial excellence, and our R&D capabilities which are the foundation for the long-term growth trajectory and the increasing impact Almirall has on people living with skin conditions, and the medical community.”

Carlos Gallardo, Almirall Chairman and CEO

Almirall, S.A. (ALM), a global biopharmaceutical company based in Barcelona, today announced its financial results for the year 2025.

Summary of results

  • Almirall met its guidance for 2025 delivering net sales of over €1bn (€1,108.1 MM) representing a year-on-year growth of 12.4%. The strong performance of the European Dermatology business and the biologics portfolio continued to be the key growth driver of the company’s sustained performance.
  • EBITDA reached €232.9 MM, increasing 20.9% year-on-year (vs. €192.2MM in 2024) in line with the guidance and long-term growth trajectory of the company. The strong sales growth achieved in 2025 continues to exceed investment growth, specifically SG&A.
  • Almirall finished 2025 with a 0x net debt to EBITDA ratio, which remains highly favourable following the continued investment in expanding the biologics portfolio.
  • Gross margin of 64.4% was in line with expectations and continues to be impacted by the sales growth of in-licensed products, especially Ilumetri®.
  • Continued investment in Research & Development of €138.1 MM, at 12.5% of net sales.
  • SG&A expenses were in line with expectations (increase of 7.9% to €501.1 MM) following the expansion of national launches of Ebglyss® across Europe to build its growth trajectory.
  • Net income was €46.2 MM (vs €10.1 MM in 2024)
  • Operating cash flow was €174.5 MM in 2025 in line with the mid to long term expectations for the company.

Advancing leadership in medical dermatology

Almirall continues to deliver its sustained growth trajectory based on a strong sales performance, mainly driven by the dermatology business in Europe which is led by the biologics portfolio as key growth driver. An increase of net sales by 12.4% YoY led to the company surpassing €1bn (net sales of €1,108.1 MM). In 2025 EBITDA delivered was €232.9 MM (increase of 20.9% YoY) with a gross margin of 64.4% confirming Almirall’s trajectory of sustained growth and margin expansion. The strong dermatology sales in Europe increased 25.6% YoY to a total of €608 MM further increasing its relevance to patients and physicians.

Atopic dermatitis and psoriasis are key indications within medical dermatology and will remain highly relevant based on the expected increase of numbers of patients diagnosed, and further opportunities for patients to benefit from advanced treatment options.

Ebglyss®, for the treatment of moderate to severe atopic dermatitis, generated €110.8 MM of sales during 2025 – demonstrating a solid increase of its market share after successful launches across European markets. The product’s growth trajectory remains in line with the expected peak sales in Europe of above €450 MM.

Ilumetri®, for the treatment of psoriasis, continued to grow in line with expectations in 2025, with net sales increasing 12.3% YoY, to a total of €234.4 MM. Anti-IL 23 antibodies remain the leading class in advanced psoriasis treatment, and the product is well positioned in this segment remaining on track to meet the expected above €300 MM peak sales target. The 200mg dose option adds flexibility to patients treated with the product, thus reinforcing its competitive profile.

Almirall’s broad dermatology product portfolio is a key factor in further building the company’s high relevance as a specialist and leader in medical dermatology with continued strong sales performance. In 2025 Wynzora® grew 30.5% YoY to a total of €33.8 MM, Klisyri® grew 33.9% YoY to a total of €32.8 MM.

R&D pipeline

Almirall’s continued investment in its leading R&D capabilities, and the medical dermatology pipeline are closely aligned with the company’s long-term view on its contributions and commitment to positively impact patients and society and with further growing its leadership in medical dermatology. In 2025 Almirall continued to invest around 12.5% of net sales in R&D, representing a total of 138.1 MM. Major pipeline achievements in 2025 include the progress of key developmental assets through clinical testing with 3 ongoing proof-of-concept (PoC)/Phase II studies including an anti-IL-1RAP monoclonal antibody (mAb) targeting hidradenitis suppurativa, an IL-2muFc mutant fusion protein targeting alopecia areata, a further inflammatory skin disease, and atopic dermatitis – the latter led by Almirall’s partner Simcere. Furthermore, Efinaconazole was approved in Germany for the treatment of nail fungal infections, and Sarecycline was approved in China for the treatment of acne.

Additional pipeline programs are expected to progress into phase II/PoC studies in the next 12 months including an anti-IL-21 monoclonal antibody targeting hidradenitis suppurativa.

Several ongoing clinical studies supporting Ebglyss® and Ilumetri® will increase the body of evidence for these important biologics and are aimed at enabling more patients to get access to the benefits of these advanced treatments. This work includes the recent announcement to start a Phase III study with lebrikizumab in patients with nummular eczema. Nummular eczema is a debilitating condition that is distinct from atopic dermatitis but is thought to involve similar disease mechanisms and therefore makes targeting IL-13 by lebrikizumab a potentially promising therapy optioni.

For tildrakizumab, the 2-year POSITIVE study presented at the 2025 European Academy of Dermatology and Venerology Congress – EADV – underpins the product’s long-term value and real-world impact on patients’ wellbeing.

Partnership with the dermatology community

Almirall’s close collaborations with dermatologists and life-science experts continue to be a key cornerstone for the company’s dedication to and success in medical dermatology. These partnerships expand Almirall’s focus on fostering scientific exchange and to advance the understanding of skin diseases, treatment options, and their impact on patients.

Almirall’s strong presence at the 2025 EADV annual congress in Paris was a demonstration of the company’s leadership in medical dermatology with the presentation of 44 scientific abstracts, two expert-led symposia on atopic dermatitis and psoriasis and with the publication of the two-year data of the POSITIVE study on Ilumetri® demonstrating the positive impact of the treatment on patients and their psychological well-being as well as the holistic approach Almirall takes to addressing patient needs.

Almirall also successfully hosted the SkinAcademy event in Barcelona in March and Almirall’s specialised ImmunoSkin event in Madrid in November 2025. These events are crucial opportunities for exchange on scientific and clinical topics in medical dermatology.

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients’ world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients’ needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2025: €1114.5 MM, over 2100 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit https://www.almirall.com/

Legal notice:

This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are “forward-looking statements.” These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly disclaims any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.

i Hagenström K, Müller K, Klinger T, Willers C, Eyerich K, Augustin M. Epidemiology of nummular eczema – methodological approaches and outcomes from nationwide claims data analyses. J Dtsch Dermatol Ges. 2025 Nov 16. doi: 10.1111/ddg.15932. Epub ahead of print. PMID: 41243467.

Contacts

Corporate Communications
corporate.communication@almirall.com
Phone: +34 93 291 35 08

Investor Relations
investors@almirall.com
Phone: (+34) 93 291 30 87

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026

Posted on by

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026




Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026

PHILADELPHIA–(BUSINESS WIRE)–Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI), in Denver, CO, that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV Functional Cure was able to “spark” and re-awaken durable HBV-specific immunity in the majority of chronically HBV-infected patients – with HBsAg declines that were sustained or deepened through Day 360. These data, presented as a late breaker presentation, by Dr. Sue Currie, PhD., Virion Therapeutics, also highlighted VRON-0200’s ongoing favorable safety and tolerability profile, and its rapid and profound synergy when combined with antigen lowering antiviral agents.


Dr. Currie commented: “We are now at a pivotal point in the development of potential functional cures for chronic HBV, with exciting progress being made, with different classes of HBV treatments. These treatments, however, are limited by their inability to restore a patient’s own immune responses against the virus. As a result, once treatment is discontinued, viral rebound typically occurs in a large proportion of patients. The field now believes that immune modulators are necessary to mitigate this virological rebound. VRON-0200 is the first new HBV immune modulator since pegylated interferon to show durable clinical activity with sustained and/or improving anti-HBV responses up to one year (360 days) following a single dose – which has the potential to prevent the need for rescue medications after HBV treatment discontinuation, and improve overall functional cure rates.” Currie added, “Additionally, the rapid HBsAg declines seen when combined with investigational antivirals, the “fan” to the VRON-0200 “spark”, has the added future potential of shortening combination treatment regimens, and also expansion to other populations such as those with higher baseline HBsAg levels (e.g., >3,000 IU/mL) and co-infected patients (e.g., HIV/HBV, HDV/HBV). This “Spark and Fan” model, where an upfront VRON-0200 “spark” dose “primes” one’s own anti-HBV immune response, then is “fanned” (boosted) by an antiviral regimen(s) that removes the virus (e.g., HBsAg), could make VRON-0200 a foundational backbone agent to a wide range of future Functional Cure strategies.”

“Locally acting checkpoint modifiers (CPM) enhance, broaden, and prolong immune responses to chronic infections and cancer, and by mechanism, minimize the risks for serious “off target” adverse events,” said Dr. Andrew Luber, Pharm.D., CEO of Virion. Luber added, “VRON-0200, Virion’s first CPM-containing immunotherapy, with its favorable safety and tolerability profile, documented durable clinical activity, and convenient single i.m. administration, along with its potential for increased accessibility due to its ease of scalabilty and distribution, make it ideal for global public health initiatives. A Phase 2b SPARK-B trial for HBV Functional Cure is in development and will use the “Spark and Fan” approach to evaluate VRON-0200 in combination with investigational antivirals. The benefits of CPM for other chronic viral diseases such as HDV/HBV, HIV/HBV, HIV Cure, HSV-2, EBV, are being considered, and the lessons learned from the VRON-0200 program are being applied to our VRON-0300 program for advanced solid tumors. We look forward to sharing more data from the current Phase 1b VRON-0200 trial at future meetings.”

The presentation is available for download at www.VirionTx.com and more details of this study can be found at ClinicalTrials.gov (Identifier: NCT06070051).

About Chronic Hepatitis B

Despite a preventative vaccine, cases of chronic hepatitis B (CHB) continue to rise, with an estimated 254 million persons infected worldwide and 1.1 million deaths per year from HBV-related liver complications. Chronic HBV remains a global health issue with a high unmet medical need since there is no cure available. The current standard of care requires lifelong antiviral therapy to maintain control of the virus. Current and investigational HBV Functional Cure treatments have been limited by their inability to restore a patient’s own immune responses against the virus. As a result, once treatment is discontinued, and the antiviral agents are no longer present, viral rebound typically occurs. As a result, immune modulators are now considered necessary for future cure treatment strategies.

About VRON-0200

VRON-0200 is an investigational therapeutic immunotherapy designed with the goal of providing a functional cure for chronic HBV infection. Clinical data from an ongoing Phase 1b trial have shown VRON-0200 to be safe and well tolerated, and, when given as a single intramuscular dose, was immunogenic, and able to “Spark” anti-HBV activity in chronically HBV-infected patients on nucleos(t)ide therapy alone, and, also, when given with combination antiviral therapies. These results suggest the potential of VRON-0200 to be the key backbone immune modulator for HBV functional cure treatments.

About Virion Therapeutics (Virion)

Virion Therapeutics, LLC is a clinical-stage company developing novel immunotherapies that utilize proprietary checkpoint modifiers to enhance/restore, broaden, and elicit sustained immune responses, with the goal to cure cancer and chronic infectious diseases. Virion’s pipeline now includes its lead VRON-0200 clinical program, and several additional IND-enabling programs, such as its VRON-0300 oncology program for advanced solid tumors, leveraging its proprietary platform technologies.

To learn more, visit www.VirionTx.com

Contacts

Virion Therapeutics, LLC, Dr. Sue Currie, Chief Operating Officer

scurrie@viriontx.com
1-800-841-9303